Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H2, 2018

GlobalData
1094 Pages - GLDATA66185
$2,500.00

Summary

GlobalData's clinical trial report, “Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H2, 2018" provides an overview of Type 1 Diabetes (Juvenile Diabetes) clinical trials scenario. This report provides top line data relating to the clinical trials on Type 1 Diabetes (Juvenile Diabetes). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Companies Mentioned
Eli Lilly and Co
Sanofi
Pfizer Inc
ProSciento Inc
AstraZeneca Plc
Adocia SAS
MannKind Corp
C. H. Boehringer Sohn AG & Co KG
Steno Diabetes Center Copenhagen
Lexicon Pharmaceuticals Inc

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials 22
Clinical Trials by Phase in E7 Countries 24
Clinical Trials in E7 Countries by Trial Status 25
Clinical Trials by Phase 27
In Progress Trials by Phase 28
Clinical Trials by Trial Status 29
Clinical Trials by End Point Status 31
Subjects Recruited Over a Period of Time 32
Clinical Trials by Sponsor Type 33
Prominent Sponsors 34
Top Companies Participating in Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials 36
Prominent Drugs 38
Latest Clinical Trials News on Type 1 Diabetes (Juvenile Diabetes) 39
Jul 18, 2018: Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus 39
Jul 04, 2018: The GABA/Diamyd trial in the US now fully recruited 39
Jun 25, 2018: Additional Positive Afrezza Clinical Data from STAT Study to Be Presented at ADA 78th Scientific Sessions 39
Jun 25, 2018: Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes 40
Jun 25, 2018: FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic Control with Additional Benefits vs. Insulin Glargine in Patients with Type 2 Diabetes 40
Jun 25, 2018: Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen 41
Jun 24, 2018: Adding Liraglutide to Insulin Regimen for People with Type 1 Diabetes Improved Glycemic Control 42
Jun 24, 2018: Renova Therapeutics Announces an Abstract to be Presented at the Late-Breaking Scientific Session of 2018 American Diabetes Association Meeting: Urocortin-2 Gene Transfer Effectively Treats Type 1 Diabetes 43
Jun 24, 2018: Dapagliflozin as Adjunct Therapy to Insulin for People with Type 1 Diabetes May Improve Glycemic Control 43
Jun 24, 2018: Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes Care 44
Jun 23, 2018: Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care 45
Jun 23, 2018: New Data Presented at the American Diabetes Association 78th Scientific Sessions Reinforce Potential of Lilly's Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes 45
Jun 23, 2018: Dual-Hormone, Artificial Pancreas with Insulin and Pramlintide Significantly Improves Glucose Levels, Compared to Insulin-Only Artificial Pancreas 46
Jun 23, 2018: MannKind Presents Positive Afrezza Clinical Data from STAT and AFFINITY Studies at ADA 78th Scientific Sessions 46
Jun 22, 2018: vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions 47
Jun 21, 2018: Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801 47
Jun 18, 2018: Lexicon Pharmaceuticals to Present New Clinical Data at 78th American Diabetes Association Scientific Sessions 48
Clinical Trial Profile Snapshots 49
Appendix 1092
Abbreviations 1092
Definitions 1092
Research Methodology 1093
Secondary Research 1093
About GlobalData 1093
Contact Us 1094
Source 1094

List of Tables
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Region, 2018* 8
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 10
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 12
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 13
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, North America, Top Countries, 2018* 14
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 15
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 16
Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2018* 18
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 19
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 21
Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2018* 23
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 24
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 26
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Phase, 2018* 27
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 28
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 30
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 31
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 32
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 33
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 35
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 37
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38

List of Figures
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 12
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 13
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 14
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 15
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 16
Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2018* 17
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 19
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
Proportion of Type 1 Diabetes (Juvenile Diabetes) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2018* 22
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 24
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 27
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 28
Type 1 Diabetes (Juvenile Diabetes) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 31
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 32
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 33
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36
Type 1 Diabetes (Juvenile Diabetes) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38
GlobalData Methodology 1093

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports